Drug addiction is a chronic, relapsing disease characterized by compulsive drug seeking and use, despite harmful consequences. More specifically, opioid use disorder (OUD), often stemming from the misuse of prescription opioid painkillers, represents an urgent social and health crisis, responsible for approximately 50,000 yearly overdose deaths and incurring an annual burden of $78.5B in medical treatment, lost productivity and legal costs in the US (See NIDA website). While effective treatments exist for opioid overdose events, the lack of effective therapeutics for long-term abstinence and prevention of relapse highlight the pressing need for alternative approaches to study OUD. Moving beyond their direct effect on neuronal function, opioids are also known to act directly on microglia. Microglia are resident immune cells in the brain that serve as key drivers of neuroinflammation, a physiological process aimed at restoring homeostasis typically in response to a traumatic, chemical or ischemic insult to the central nervous system. A hallmark of neuroinflammation is microglial activation, and the transcriptional mechanisms underlying microglial activation operate under control of epigenetic remodeling of histone proteins. In the context of OUD, it has been previously shown that opioids can induce activation of microglia and that reduction in neuroinflammation can curb craving for opioid painkillers. Considering the known role of epigenetics in addiction and the emerging role of microglia in this disease, we propose to investigate the epigenetic underpinnings of microglial activation in OUD. More specifically, we will focus on the changes in histone lysine methylation in microglia of the brain reward system and how these changes comport with transcriptional programs across various phases of opioid- taking (maintenance, early withdrawal, and craving) by using a mouse model of intravenous remifentanil self-administration (IVSA). Furthermore, we will explore the role of this epigenetic modification in regulating opioid-induced microglial activation, opioid-seeking and relapse by pharmacological and genetic manipulation of Kdm6b, a histone lysine demethylase enriched in microglia. In conclusion, results from these experiments have the potential to not just broaden our understanding of the epigenetic mechanisms underlying OUD, but rather push the field of addiction epigenetics beyond the neuron and into cell types that could yield exciting new therapeutic avenues for the treatment this devastating disease.

Public Health Relevance

Opioid use disorder (OUD) represents an urgent public health crisis for which available therapeutics have proven insufficiently efficacious. While most of the research surrounding opioid addiction has focused on how neurons communicate with one another, less attention has been given to other brain cell types and mechanisms that have also been shown to affect aspects of addiction, such as neuroinflammation induced by microglia ? the resident immune cells of the central nervous system. Given that microglial activation is under epigenetic control, the proposed research seeks to understand the epigenetic mechanisms that govern microglial activation across different phases of OUD, with the goal of developing more effective therapeutics for this devastating disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
1DP1DA051828-01
Application #
10051132
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Satterlee, John S
Project Start
2020-07-01
Project End
2025-05-31
Budget Start
2020-07-01
Budget End
2021-05-31
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Psychiatry
Type
Schools of Medicine
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146